Gathering the record
Relay is organizing the evidence and source boundaries.
Synthetic tetrapeptide
An experimental peptide marketed around heart-health claims. Its organ-related name does not establish a benefit.
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Why people look into it, what studies found, and what is still unknown.
Educational information only. Evidence reviewed through July 31, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Each label shows how much evidence supports that question.
What studies show
No controlled administered-human Cardiogen study was located.
This is the strongest human-evidence boundary in the current record.
Mechanistic findings explain biological plausibility; they do not establish a human outcome.
Relay keeps this uncertainty visible rather than converting it into a prediction.
The safety snapshot reflects the studied record and its limitations.
Regulatory and identity status determine how the evidence should be interpreted.
Risks & unknowns
Current evidence cannot yet resolve: Human pharmacology, target engagement, cardiovascular outcomes, tumor-related interpretation, and longer-term safety.
No direct evidenceAn absence of adequate evidence is not evidence of benefit, harm, or equivalence.
Open sourceThe available information does not reliably show how often particular side effects occur.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
Relay has not verified which side effects led people to stop treatment in studies.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
Relay has not verified a compound-specific warning summary for this profile.
Evidence boundaryPreclinical; no FDA-approved Cardiogen/AEDR product. Human pharmacology, target engagement, cardiovascular outcomes, tumor-related interpretation, and longer-term safety.
This profile does not contain verified, product-specific emergency instructions.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
The reviewed evidence does not establish an administered-human regimen for the exact Cardiogen peptide. Organ-extract products are not interchangeable.
What would fill this gap: A direct human study identifying the synthetic peptide and full regimen.
Dosing review checked Oct 20, 2026. Additional sources are available below.No route-specific preparation instructions were verified. A different route or product does not supply them.
Starting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
Published research investigated AEDR in a controlled rat tumor model to explore growth-related questions around the peptide's preclinical biology.
Population: Rats
Design: Controlled animal tumor study
Mechanisms
AEDR experiments explore gene-expression, cell-growth, and tissue effects. The available record does not establish a human cardiovascular treatment.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
No single validated target is established in the current record.
Research reference
A reference for the studies, populations, and routes behind this profile.
Laboratory and animal evidence; no controlled administered-human efficacy study located.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Human pharmacology, target engagement, cardiovascular outcomes, tumor-related interpretation, and longer-term safety.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: No verified controlled administered-human Cardiogen study was located. A rat tumor experiment cannot establish human cardiovascular benefit, cancer risk, pharmacology, or safety. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Controlled animal tumor study
Rats
Endpoints were not fully described in the current record.
AEDR was evaluated in an animal tumor model to explore growth-related safety questions.
Study administration: Not stated in the current record.
Limitations: Does not establish human cancer risk or cardiovascular benefit.
Narrative review
Population not stated.
Endpoints were not fully described in the current record.
A review summarizes mostly laboratory and animal work on organ-specific peptide hypotheses.
Study administration: Not stated in the current record.
Limitations: Review and mechanistic evidence do not replace direct clinical trials.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
PMID 20396706
PMID 34830335